News & Updates
Filter by Specialty:
FASN inhibitor for MASH with fibrosis gets a pass to phase III
The oral fatty acid synthase (FASN) inhibitor denifanstat appears to produce meaningful improvements in metabolic dysfunction-associated steatohepatitis (MASH) and stage 2–3 fibrosis, as shown in the results of a phase IIb trial.
FASN inhibitor for MASH with fibrosis gets a pass to phase III
28 Oct 2024
Survodutide safe to use in cirrhosis patients
Treatment with survodutide, which has previously shown its efficacy in reducing body weight and glycaemia in people with obesity or type 2 diabetes, is well tolerated by patients with compensated or decompensated cirrhosis, reports a study.
Survodutide safe to use in cirrhosis patients
27 Oct 2024
Opioid use ups healthcare use, costs in adults with PsA, AS
Patients with psoriatic arthritis (PsA) and ankylosing spondylitis (AS) who use opioids end up with higher healthcare utilization and costs compared with those who do not use opioids, reports a study.
Opioid use ups healthcare use, costs in adults with PsA, AS
24 Oct 2024
Semaglutide helps prevent HF events, CV death in diabetic patients with CKD
Treatment with semaglutide can significantly lower the risk of time to first heart failure (HF) events or cardiovascular (CV) death in type 2 diabetes (T2D) patients with chronic kidney disease (CKD), a recent study has shown.
Semaglutide helps prevent HF events, CV death in diabetic patients with CKD
24 Oct 2024
Statins may prevent deaths in hospitalized COVID-19 patients
Use of statins helps prevent deaths in patients hospitalized with COVID-19, as shown by the results of a systematic review and meta-analysis.
Statins may prevent deaths in hospitalized COVID-19 patients
22 Oct 2024
DISCREET highlights apremilast potential for genital psoriasis
Individuals with psoriasis creeping into their intimate areas may find relief from apremilast, as shown by the week-32 improvements in multiple disease parameters in the phase III DISCREET study.